| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJROBP.2007.11.044 |
| P698 | PubMed publication ID | 18313526 |
| P50 | author | Margie Hunt | Q37836469 |
| Michael J Zelefsky | Q51936867 | ||
| Yoshiya Yamada | Q88988860 | ||
| Howard I Amols | Q117216231 | ||
| Alison M Shippy | Q117216239 | ||
| P2093 | author name string | Andrew Jackson | |
| Emily J Levin | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1124-1129 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer | |
| P478 | volume | 70 |
| Q26824593 | Q26824593 |
| Q43379636 | 2D kV orthogonal imaging with fiducial markers is more precise for daily image guided alignments than soft-tissue cone beam computed tomography for prostate radiation therapy |
| Q42906342 | 3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study. |
| Q37776778 | A Review of the Clinical Evidence for Intensity-modulated Radiotherapy |
| Q62746524 | A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer |
| Q35202412 | A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer |
| Q39252193 | A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer |
| Q42116748 | A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes |
| Q28972349 | A national survey of the availability of intensity-modulated radiation therapy and stereotactic radiosurgery in Canada |
| Q38640375 | A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy. |
| Q30613075 | A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada |
| Q38417823 | A simple algorithm to assess patient suitability for Calypso-seed implantation for four-dimensional prostate localization |
| Q38981805 | Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancer |
| Q42097767 | Accuracy of dose planning for prostate radiotherapy in the presence of metallic implants evaluated by electron spin resonance dosimetry |
| Q85173928 | Acute and Late Toxicity After Dose Escalation to 82 GyE Using Conformal Proton Radiation for Localized Prostate Cancer: Initial Report of American College of Radiology Phase II Study 03-12 |
| Q48141226 | Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer |
| Q40374784 | Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. |
| Q33707219 | Assessment and Comparison of Homogeneity and Conformity Indexes in Step-and-Shoot and Compensator-Based Intensity Modulated Radiation Therapy (IMRT) and Three-Dimensional Conformal Radiation Therapy (3D CRT) in Prostate Cancer |
| Q64083346 | Assessment of chronic radiation proctopathy and radiofrequency ablation treatment follow-up with optical coherence tomography angiography: A pilot study |
| Q46439191 | Associations between volume changes and spatial dose metrics for the urinary bladder during local versus pelvic irradiation for prostate cancer |
| Q42282596 | Body mass index can affect gastrointestinal and genitourinary toxicity in patients with prostate cancer treated with external beam radiation therapy |
| Q36421373 | Certificate of need regulations and the diffusion of intensity-modulated radiotherapy |
| Q38211358 | Challenges of managing elderly men with prostate cancer |
| Q33659901 | Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer |
| Q85575044 | Clinical effect of multileaf collimator width on the incidence of late rectal bleeding after high-dose intensity-modulated radiotherapy for localized prostate carcinoma |
| Q84146370 | Clinical implementation of volumetric intensity-modulated arc therapy (VMAT) with ERGO++ |
| Q39724232 | Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer |
| Q36922615 | Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol |
| Q48623725 | Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer |
| Q34026731 | Comparative effectiveness of external-beam radiation approaches for prostate cancer |
| Q90018871 | Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting |
| Q86531815 | Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer |
| Q55665448 | Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer. |
| Q64988846 | Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer. |
| Q37601093 | Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer. |
| Q38848137 | Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer |
| Q51084303 | Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT. |
| Q90646730 | Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy |
| Q55152678 | Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice. |
| Q48325008 | Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance |
| Q64979333 | Developing a multivariable normal tissue complication probability model to predict late rectal bleeding following intensity-modulated radiation therapy. |
| Q38109258 | Developments in external beam radiotherapy for prostate cancer |
| Q28552864 | Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? |
| Q89942055 | Dose escalation (81 Gy) with image-guided radiation therapy and volumetric-modulated arc therapy for localized prostate cancer: A retrospective preliminary result |
| Q33679365 | Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes |
| Q33466566 | Dose impact of rectal gas on prostatic IMRT and VMAT. |
| Q36423676 | Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer |
| Q36215731 | Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis |
| Q36575937 | Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes |
| Q50077685 | Dynamics of rectal balloon implant shrinkage in prostate VMAT : Influence on anorectal dose and late rectal complication risk |
| Q33672832 | Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system |
| Q43276195 | Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study |
| Q35047440 | Effects of prostate-rectum separation on rectal dose from external beam radiotherapy |
| Q92923025 | Elective Node Irradiation With Integrated Boost to the Prostate Using Helical IMRT-Clinical Outcome of the Prospective PLATIN-1 Trial |
| Q28076526 | Endoscopic and non-endoscopic approaches for the management of radiation-induced rectal bleeding |
| Q36081918 | Epidemiology of prostate cancer and treatment remarks |
| Q36989128 | Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario. |
| Q58130546 | Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking |
| Q33922185 | Evidence based radiation oncology with existing technology |
| Q26849735 | Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment |
| Q36921562 | Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma |
| Q36166886 | Feasibility of normal tissue dose reduction in radiotherapy using low strength magnetic field |
| Q36997694 | Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT). |
| Q36406313 | Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse |
| Q58753445 | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
| Q82770837 | High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer |
| Q89356145 | High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes |
| Q57280845 | Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline |
| Q36798868 | Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study |
| Q39932645 | Image guided dose escalated prostate radiotherapy: still room to improve |
| Q41898795 | Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results. |
| Q40412725 | Image-guided intensity-modulated radiation therapy decreases late gastrointestinal side effects after radiation therapy for prostate cancer |
| Q57112512 | Image-guided radiotherapy for prostate cancer |
| Q55295386 | Impact of different biologically-adapted radiotherapy strategies on tumor control evaluated with a tumor response model. |
| Q42259632 | Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. |
| Q53119315 | Impact of inter- and intrafraction deviations and residual set-up errors on PTV margins. Different alignment techniques in 3D conformal prostate cancer radiotherapy. |
| Q98466227 | Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials |
| Q41841932 | Intensity Modulated Radiation Therapy Reduces Gastrointestinal Morbidity in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer |
| Q35124022 | Intensity modulated radiotherapy (IMRT) for patients of the Brazilian unified health system (SUS): an analysis of 508 treatments two years after the technique implementation. |
| Q35069296 | Intensity modulated radiotherapy for elderly bladder cancer patients |
| Q53164682 | Intensity-Modulated Radiotherapy Reduces Gastrointestinal Toxicity in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer |
| Q34268907 | Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer |
| Q61809595 | Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis |
| Q40827296 | Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial |
| Q42794419 | Late rectal and bladder toxicity following radiation therapy for prostate cancer: Predictive factors and treatment results |
| Q92757983 | Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer |
| Q37250946 | Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study |
| Q64102847 | Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study |
| Q45036312 | Long-term outcomes for men with high-risk prostate cancer treated definitively with external-beam radiotherapy with or without androgen deprivation |
| Q46001813 | Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer. |
| Q90636971 | Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer |
| Q37480893 | Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study |
| Q34786513 | Long-term urinary adverse effects of pelvic radiotherapy |
| Q41096946 | Management of bladder neck stenosis and urethral stricture and stenosis following treatment for prostate cancer. |
| Q35503645 | Management of high-risk localized prostate cancer |
| Q92969050 | Management of radiation-induced proctitis |
| Q38150246 | Management of radiation-induced rectal bleeding |
| Q64076380 | Maximizing rectal dose sparing with hydrogel: A retrospective planning study |
| Q83394120 | Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy. First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial |
| Q37787414 | Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusing on the Incidence of Late Rectal Toxicities |
| Q43906056 | Nomograms to predict late urinary toxicity after prostate cancer radiotherapy |
| Q24185868 | Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis |
| Q49834246 | Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer |
| Q85206267 | Osteosarcoma after radiotherapy for prostate cancer |
| Q34696349 | Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer |
| Q37717598 | Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer |
| Q36634718 | Parameters Favorable to Intraprostatic Radiation Dose Escalation in Men With Localized Prostate Cancer |
| Q28280008 | Past, present, and future of radiotherapy for the benefit of patients |
| Q84187684 | Patient positioning variations to reduce dose to normal tissues during 3D conformal radiotherapy for high-risk prostate cancer |
| Q36672787 | Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity |
| Q41196537 | Polaprezinc protects normal intestinal epithelium against exposure to ionizing radiation in mice |
| Q50002077 | Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapy |
| Q46789311 | Postprostatectomy ultrasound-guided transrectal implantation of gold markers for external beam radiotherapy. Technique and complications rate. |
| Q43246964 | Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer |
| Q37526775 | Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues |
| Q41955928 | Preliminary analysis of risk factors for late rectal toxicity after helical tomotherapy for prostate cancer |
| Q35812261 | Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial |
| Q84509906 | Preliminary results of intensity-modulated radiation therapy with helical tomotherapy for prostate cancer |
| Q41981580 | Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial |
| Q84484657 | Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis |
| Q34748877 | Proctitis following stereotactic body radiation therapy for prostate cancer |
| Q35167186 | Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis |
| Q36093423 | Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. |
| Q45212989 | Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. |
| Q34556112 | Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. |
| Q42165844 | Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer |
| Q38993013 | Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy |
| Q37578562 | Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know? |
| Q45936840 | Prostate and seminal vesicle volume based consideration of prostate cancer patients for treatment with 3D‐conformal or intensity‐modulated radiation therapya) |
| Q41886788 | Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes |
| Q37763709 | Prostate cancer screening 2010: updated recommendations from the American Cancer Society |
| Q41960185 | Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT). |
| Q89869696 | Proton therapy- the modality of choice for future radiation therapy management of Prostate Cancer? |
| Q37796535 | Proton-Beam Therapy for Prostate Cancer |
| Q36391909 | Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients |
| Q37686901 | Quality of Life and Sexual Health in the Aging of PCa Survivors |
| Q42614935 | Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial |
| Q34111590 | Radiation Therapy in Prostate Cancer: A Risk-Adapted Strategy |
| Q35870610 | Radiation dose-volume effects in radiation-induced rectal injury |
| Q36655284 | Radiation dose-volume effects of the urinary bladder |
| Q39448990 | Radiation proctitis: current strategies in management |
| Q38432682 | Radical prostatectomy versus external beam radiotherapy for localized prostate cancer: Comparison of treatment outcomes |
| Q45741346 | Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. |
| Q64108927 | Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy |
| Q37308234 | Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer |
| Q38364578 | Radiotherapy for high-risk prostate cancer |
| Q84465912 | Randomized clinical trial of postoperative strontium-90 radiation therapy for pterygia: treatment using 30 Gy/3 fractions vs. 40 Gy/4 fractions |
| Q36127793 | Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy. |
| Q53766555 | Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. |
| Q38106626 | Reducing rectal injury during external beam radiotherapy for prostate cancer |
| Q41276603 | Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives |
| Q48824966 | Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study |
| Q89769931 | Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions |
| Q37255064 | Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs |
| Q43189608 | Respiratory-induced prostate motion using wavelet decomposition of the real-time electromagnetic tracking signal |
| Q35248634 | Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer |
| Q40607482 | Risk of hospitalisation after primary treatment for prostate cancer |
| Q37951792 | Role of radiation therapy for the treatment of lymph nodes in urologic malignancies |
| Q35073996 | SIU/ICUD Consultation on Urethral Strictures: Posterior urethral stenosis after treatment of prostate cancer |
| Q42070586 | Salvage helical tomotherapy for prostate cancer recurrence following definitive external beam radiotherapy: A case report |
| Q42571229 | Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding |
| Q28304984 | Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation |
| Q38268325 | Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)). |
| Q36326326 | Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397). |
| Q26772255 | Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer |
| Q35024218 | Systematic review: anal and rectal changes after radiotherapy for prostate cancer |
| Q44653206 | Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer |
| Q28552007 | The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures |
| Q37510070 | The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning |
| Q58656934 | The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy |
| Q40289101 | The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer |
| Q37385284 | The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients |
| Q36259082 | The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer |
| Q39365194 | The radiation dose-regulated AND gate genetic circuit, a novel targeted and real-time monitoring strategy for cancer gene therapy |
| Q87671063 | The role of TRAIL in fatigue induced by repeated stress from radiotherapy |
| Q36156751 | Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes |
| Q82355774 | Time course of late rectal toxicity after radiation therapy for prostate cancer |
| Q38152713 | Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial |
| Q85125251 | Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer |
| Q39375431 | Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer |
| Q41994836 | Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer |
| Q38611189 | Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial |
| Q34500966 | Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis |
| Q42248178 | Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer |
| Q85166705 | Tumour Shrinkage and Contour Change during Radiotherapy Increase the Dose to Organs at Risk but not the Target Volumes for Head and Neck Cancer Patients Treated on the TomoTherapy HiArt™ System |
| Q85115709 | Twice-Weekly Hypofractionated Intensity-Modulated Radiotherapy for Localized Prostate Cancer With Low-Risk Nodal Involvement: Toxicity and Outcome From a Dose Escalation Pilot Study |
| Q90717996 | Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial |
| Q28067904 | Urethral strictures after radiation therapy for prostate cancer |
| Q46149480 | Use of hydrogel as spacer in Denovier's space: optimization of IMRT radiotherapy of localized prostate cancer |
| Q38112877 | Validating a claims-based method for assessing severe rectal and urinary adverse effects of radiotherapy |
| Q30461426 | Volumetric modulated arc therapy: a review of current literature and clinical use in practice. |
| Q38412788 | What is the best way to radiate the prostate in 2016? |
| Q37549491 | Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report |
| Q41897302 | Whole-pelvic volumetric-modulated arc therapy for high-risk prostate cancer: treatment planning and acute toxicity |
| Q51162875 | [Prostate cancer 2010. Therapeutic innovations]. |
| Q82728740 | [Prostate cancer] |
| Q53285380 | [Treatment of vesico-enteric fistulae in men. Pedicled bladder flap]. |
Search more.